Kala Bio (KALA) Net Equity Issued and Repurchased (2018 - 2026)
Kala Bio (KALA) posted Net Equity Issued and Repurchased of $4.1 million for Q1 2026, up 344.42% sequentially from $923000.0 in Q4 2024.
Kala Bio (KALA) Net Equity Issued and Repurchased (2018 - 2026) Analysis & Trends
Kala Bio has reported Net Equity Issued and Repurchased for 7 years, with the latest figure at $4.1 million in Q1 2026.
- Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.5 million (changed N/A YoY) and the FY2025 annual result came in at $1.8 million, down 46.97% from the prior year.
- Net Equity Issued and Repurchased advanced to $4.1 million in Q1 2026 per KALA's latest filing, from $923000.0 in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $14.9 million in Q1 2023 and troughed at $570000.0 in Q4 2023.
- A 3-year average of $4.8 million and a median of $3.6 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
- The widest YoY moves for Net Equity Issued and Repurchased: up 61.93% in 2024, down 61.93% in 2024.
- Over 3 years, Net Equity Issued and Repurchased stood at $570000.0 in 2023, then surged by 61.93% to $923000.0 in 2024, then soared by 344.42% to $4.1 million in 2026.
- According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $4.1 million, $923000.0, and $4.9 million for Q1 2026, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Kala Bio | 9.89 Mn | 9.89 Mn | - | 4.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.10 Mn |
| Mar 31, 2026 | 4.10 Mn |
| Dec 31, 2024 | 923,000.00 |
| Dec 31, 2024 | 923,000.00 |
| Sep 30, 2024 | 4.94 Mn |
| Sep 30, 2024 | 4.94 Mn |
| Dec 31, 2023 | 570,000.00 |
| Dec 31, 2023 | 570,000.00 |
| Jun 30, 2023 | 3.07 Mn |
| Jun 30, 2023 | 3.07 Mn |
| Mar 31, 2023 | 14.89 Mn |
| Mar 31, 2023 | 14.89 Mn |
| Dec 31, 2021 | 169,000.00 |
| Dec 31, 2021 | 169,000.00 |
| Sep 30, 2021 | 333,000.00 |
| Sep 30, 2021 | 333,000.00 |
| Jun 30, 2021 | 6.02 Mn |
| Jun 30, 2021 | 6.02 Mn |
| Mar 31, 2021 | 34.71 Mn |
| Mar 31, 2021 | 34.71 Mn |